N-Power Medicine, a leader in revolutionizing the clinical trial process, announced the acquisition of Syapse Holdings a pioneer in precision medicine solutions for community cancer centers.
This integration combined Syapse’s expansive network of over 1,000 oncologists in community-based health systems, along with its advanced data, technology stack, and dedicated team. The acquisition enhanced N-Power Medicine’s capabilities in oncology clinical research and trials.
N-Power partnered with community oncologists through its proprietary real-time Kaleido Registry and AI-enabled point-of-care platform, supplemented by virtual and on-site support, to optimize research and patient care workflows. This transaction established the largest community-based prospective clinical research network, where every patient, through N-Power’s platform, had research-ready data and documentation as part of their routine care. The expanded N-Power network also helped address critical gaps in patient access to clinical trials in the community setting, where more than 80% of U.S. cancer patients, particularly those from diverse and underrepresented populations, received their care.
The transaction enhanced the company’s current offerings to its growing set of pharmaceutical customers, including Merck, which was engaged in a multi-trial collaboration with N-Power. N-Power was able to provide significantly greater access to a more representative group of geographically diverse, U.S. community-based cancer patients for clinical trial enrollment. The increased network scale also enabled the rapid and rigorous generation of prospective external controls, allowing for smaller and faster clinical trials.
Mark Lee, M.D., Ph.D, the Co-Founder and Chief Executive Officer of N-Power Medicine, added:
“The integration of Syapse into N-Power underscores our commitment to dramatically accelerating drug development and improving the probability of success by seamlessly integrating clinical research into every oncologist’s practice and every cancer patient’s care. With this scale, N-Power accelerates the transformation of drug development that our pharma customers are asking for – enabling local access to clinical trials for more community oncologists and community cancer patients than ever before, and by creating a unique platform for generating prospective external controls, reducing the need for randomized trials.”
About N-Power Medicine
N-Power Medicine is a clinical research and drug development platform company focused on significantly increasing clinical trial participation to expedite oncology drug development and deliver life-saving innovations to cancer patients. Founded in 2021, the company addresses critical challenges for oncology sites by integrating technology and trained personnel into routine care, unlocking the full potential of the data necessary to bring new therapies to patients more quickly.
About Syapse
Syapse is a company focused on alleviating the fear and burden of oncology and other serious diseases by advancing real-world care. Through a combination of clinical expertise and innovative technologies, Syapse transforms vast amounts of data into actionable evidence that improves patient outcomes. The company works alongside a network of partners, including healthcare providers and research institutions, all committed to enhancing patients’ lives through community-based health systems.
By leveraging real-world evidence and advanced technologies, Syapse plays a pivotal role in making healthcare more personalized and efficient. Its efforts aim to bridge gaps in access to quality care, particularly in underserved communities, helping to ensure that patients receive the most effective treatments based on the latest research and clinical insights.